ArticleBMC cancer2026
Study on the anti-lung cancer effects of Gracillin from Reineckia carnea by targeting STC1.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGracillin, a steroidal saponin isolated from Reineckia carnea, exhibits broad anti-tumor activity. However, current studies on its mechanisms of action against lung cancer remain scarce, necessitating further investigation to elucidate the specific targets of its anti-tumor activity. This study aims to preliminarily elucidate the effects of Gracillin against human non-small cell lung cancer (NSCLC) cells and its potential mechanisms.
methodsNCI-H1299 cells were selected for in vitro cell experiments. Gracillin's cytotoxic, pro-apoptotic and anti-metastatic effects were assessed by CCK-8, flow cytometry, wound healing, Transwell assays and Western Blot. Potential target STC1 was identified through RNA-sequencing and validated via RT-qPCR, ELISA, and immunofluorescence. Interaction between Gracillin and STC1 was confirmed by molecular docking and SPR. STC1 knockdown and pathway inhibitors were applied to explore the role of STC1 and MAPK/ERK signaling in Gracillin's actions.
resultsGracillin inhibited proliferation, migration, invasion and induced apoptosis in NCI-H1299 cells. RNA-sequencing and validation assays identified that STC1's expression and secretion were upregulated by Gracillin. Direct binding between Gracillin and STC1 was confirmed by the values of molecular docking and SPR. Then, knockdown of STC1 attenuated Gracillin's anti-tumor effects and suppressed its activation of the ERK pathway. Furthermore, the inhibition of ERK pathway reversed Gracillin-mediated suppression of proliferation, migration and invasion.
conclusionsGracillin exerts its inhibitory effects on the proliferation, migration, and invasion of NCI-H1299 cells by targeting STC1 protein, upregulating STC1 protein level, and subsequently activating the ERK signaling pathway. Gracillin holds promise as a targeted therapeutic agent for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.